

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00
Thursday, October 5

Chair Persons: E. Agostinelli, S. Roche, S. Assinder

156. The oncogenic role of the collagen receptor DDR1 and the pseudo-kinase Pragmin in metastatic colorectal cancer. C. Lecointre, M. Jeitany, C. Leroy, P. Tosti, V. Simon, F. Allemand, A. Fournet, M. Gelin, A. Sirvent, G. Labesse, **S. Roche** (Montpellier, France) (30')
155. Evidence for oxytocin induced cholesterol synthesis in endocrine related cancers. **S. Assinder**, V. Bhopalan, A. Novo (Sydney, Australia) (30')
188. Polyamine metabolites induce apoptosis in cancer cells detected by real time RT-PCR and mass spectroscopy analyses. **E. Agostinelli**, A. Finotti, Y. Kanamori, J. Gasparello, S. Ohkubo, F. Timeus, S. Merali, R. Gambari (Rome; Ferrara; Turin, Italy; Philadelphia, PA, USA) (30')
137. Involvement of cancer extracellular vesicles in the transition from normal to cancer associated fibroblasts. **I. Giusti**, M. Di Francesco, S. D'Ascenzo, V. Dolo (L'Aquila, Italy) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00
Thursday, October 5

Chair Persons: H. Modjtahedi, C.M. Wells

133. Therapeutic and diagnostic applications of monoclonal antibodies in pancreatic cancer: Advances and challenges. G.A. Arias-Pinilla, A. Dalgleish, S. Mudan, **H. Modjtahedi** (London, UK) (30')
113. Novel PAK4 pathways to drive cancer cell invasion; opportunities for targeted therapy. N. Nicholas, H. King, K. Thillai, A. Pipili, M. Lesjak, **C.M. Wells** (London, UK) (30')
264. Regulation of EGFR family receptors by NF-E2-related factor 2 (NRF2) and its implication for the anticancer effectiveness of EGFR targeting RTK inhibitors. I.H. Kankia, H.S. Khalil, S.P. Langdon, D.J. Harrison, J.L. Bown, **Y.Y. Deeni** (Dundee; Scotland; St Andrews, UK) (30')

CANCER THERAPEUTICS

Room A, 16:00-17:30
Thursday, October 5

Chair Persons: S. Oltean, U. Naumann

174. Modulators of alternative splicing as novel therapeutics in cancer. L. Ling, **S. Oltean** (Exeter, UK) (30')
115. Carboxypeptidase E transmits its anti-migratory function in glioma cells via transcriptional regulation of cell architecture and motility regulating factors as well as by changing metabolism. A. Armento, E.I. Ilina, T. Kaoma, A. Muller, L. Garea, C. Penski, L. Jennewein, P.N. Harter, L. Vallar, S. Niclou, S. Zukunft, I. Fleming, D. Schulte, M. Krüger, F. Le Guerroue, C. Behrends, M.W. Ronellenfitsch, M. Mittelbronn, **U. Naumann** (Tübingen; Frankfurt; Heidelberg, Germany; Luxembourg) (30')
104. Exosomes, tumor microenvironment and therapeutic use of microRNAs. **G. Glady** (Colmar, France) (30')

microRNAs

Room A, 18:00-19:30
Thursday, October 5

Chair Persons: G. Glady, C. Romero

103. MicroRNAs regulating metabolic reprogramming of cancer cells. **G. Glady** (Colmar, France) (30')
118. Role of microRNA-23b in epithelial ovarian cancer and its regulation by nerve growth factor. **C. Romero**, A. Hernandez, P. Cuevas, R. Retamales, C. Vera, M. Vega (Santiago, Chile) (30')
172. MicroRNAs - potencial targets for Parkinson's gene therapy. **C.H. Horst** (Brasília, Brazil) (30')

IMMUNOLOGY/HYPOXIA

Room B, 09:00-11:00
Thursday, October 5

Chair Persons: S.N. Karagiannis, V. Jurisic

177. Reprogramming macrophages against cancer cells with monoclonal antibodies. **S.N. Karagiannis** (London, UK) (30')
256. Analyses of CD38 cells isolated from bone marrow of patients with multiple myeloma by immunomagnetic methods. **V. Jurisic**, K. Mirjagic-Martinovic, A. Radovanovic, O. Markovic, M. Radojkovic, G. Konjevic (Kragujevac; Belgrade, Serbia) (30')
122. GD2 ganglioside-binding antibody and specific aurora A kinase inhibitor induce autophagy in IMR-32 neuroblastoma cells. **M. Durbas**, P. Pabisz, K. Wawak, E. Boratyn, I. Nowak, I. Horwacik, H. Rokita (Kraków, Poland) (20')
171. Functions of anti-V2 antibodies which may play a role in protection against HIV-1 infection. **M.K. Gorny** (New York, NY, USA) (20')
319. Anticancer efficacy of the hypoxia-activated pro-drug evofosfamide in preclinical osteosarcoma murine models. **V. Liapis**, A. Labrinidis, I. Zinonos, S. Hay, V. Ponomarev, V. Panagopoulos, M. DeNichilo, W. Ingman, G.J. Atkins, D.M. Findlay, A. Evdokiou (Adelaide, South Australia; New York, NY, USA) (20')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:10
Thursday, October 5

Chair Persons: N. Kentepozidis, A. Cimini

189. CXCR1/2 pathways in paclitaxel-induced neuropathic pain. L. Brandolini, E. Benedetti, P.A. Ruffini, R. Russo, L. Cristiano, A. Antonosante, M. D'Angelo, V. Castelli, A. Giordano, M. Allegretti, **A. Cimini** (L'Aquila; Milano; Naples; Siena; Assergi, Italy; Philadelphia, PA, USA) (20')
253. Immunotherapy for lung cancer. **N. Kentepozidis** (Athens, Greece) (20')
186. Targeting Gli acetylation in Shh-medulloblastoma: A successful preclinical approach. **S. Coni**, L. Di Magno, A.B. Mancuso, G. Sdruscia, S. Manni, S.M. Serrao, L. Di Marcotullio, E. De Smaele, E. Ferretti, G. Canettieri (Rome, Italy) (20')
190. Promoter methylation of MGMT is an important predictor of the clinical course of pilocytic astrocytoma. **C. Sippl**, S. Urbschat, Y.J. Kim, S. Senger, J. Oertel, R. Ketter (Homburg/Saar, Germany) (20')
304. TGF- β 1 (in)dependent wound therapy: Should open excisions and sutured incisions be treated differently? **P. Gál**, T. Vasilenko, I. Kováč, M. Novotný, P. Szabo, L. Varinská, H.-J. Gabius, K. Smetana Jr (Košice, Slovakia; Prague, Czech Republic; Munich, Germany) (20')

METASTASIS/PROGRESSION/APOPTOSIS

Room B, 16:00-17:30
Thursday, October 5

Chair Persons: N. Jahroudi, F. Vallette

223. Association of endothelial specific procoagulant molecule von willebrand factor with cancer progression. **N. Jahroudi** (Edmonton, Canada) (30')
290. Mitochondria associated membranes (MAMs) are associated with early steps of intrinsic apoptosis. **F. Vallette**, V. Mignard, L. Lalier, L. Oliver, F. Paris (Nantes, France) (30')
267. JAK2V617F, CALR and MPL mutations and bone marrow histology in patients with essential thrombocythemia. **A. Pich**, L. Riera, P.F. Di Celle, E. Beggiato, G. Benevolo, L. Godio (Turin, Italy) (30')

MOLECULAR ONCOLOGY/MOLECULAR MEDICINE

Room B, 18:00-19:30
Thursday, October 5

Chair Persons: P. Rosa, W. Brenner

219. Molecular mechanisms underlying myelination defects in Down's syndrome. A. Ulivi, V. Meraviglia, N. Colombo, M. Boccazzi, M.P. Abbracchio, R. Bartesaghi, S. Ceruti, **P. Rosa** (Milan; Bologna, Italy) (30')
143. The role of the splice variant PTENdelta in tumor progression. I. Breuksch, M. Schmidt, J. Hengstler, K. Edlund, S. Gebhard, D. Prawitt, A. Hasenburg, **W. Brenner** (Dortmund; Mainz, Germany) (30')
266. Fibroblast activation protein- α (FAP- α) expression in squamous cell carcinoma of the esophagus in primary and irradiated tumors. Molecular techniques and immunohistochemistry on frozen and formalin-fixed tissues. **R. Tabola**, M. Zaremba-Czogalla, D. Baczynska, R. Cirocchi, K. Stach, K. Grabowski, K. Augoff (Wroclaw, Poland; Perugia, Italy) (30')

BIOMARKER DISCOVERY/CLINICAL ONCOLOGY

Room C, 09:00-11:00
Thursday, October 5

Chair Persons: J.A. Martignetti, C. Riganti

215. The Pandora's box of precision molecular diagnostics: Genomic analysis reveals both early stage cancers but also clones of indeterminate potential. N. Nair, O. Camacho-Vanegas, D. Rykunov, M. Dashkoff, S.C. Camacho, C.A. Schumacher, J.C. Irish, T.T. Harkins, E. Pereira, S. Kendall, N. Nagarsheth, T. Kalir, R. Sebra, B. Reva, P. Dottino, **J.A. Martignetti** (New York, NY; Ann Arbor, MI; Philadelphia, PA; Danbury, CT, USA) (25')
151. Carbonic anhydrase 12: A new biomarker and a new therapeutic target in multidrug resistant tumors. J. Kopecka, I.C. Salaroglio, G.M. Rankin, P. Mujumdar, L. Annovazzi, M. Mellai, D. Schiffer, B. Wollscheid, S.-A. Poulsen, **C. Riganti** (Torino; Vercelli, Italy; Brisbane, Australia; Zurich, Switzerland) (25')
216. Applying precision medicine to ovarian cancer: A 'molecular second look' diagnostic and prognostic test. M. Schwartz, O. Camacho-Vanegas, A. Wood, M. Dashkoff, C. Whitelock, T. Harkins, A.M. Beddoe, P. Dottino, **J.A. Martignetti** (New York, NY; Ann Arbor, MI; Danbury, CT, USA) (20')
144. Application of next generation sequencing to molecular diagnosis and disease gene identification in childhood malignancies. **S. Heinsohn**, K. Lehmborg, U. zur Stadt (Hamburg, Germany) (20')
220. Human placental growth hormone in normal and abnormal fetal growth. **A. Velegrakis**, M. Sfakiotaki, S. Sifakis (Heraklion, Greece) (15')
316. Lipogenesis inhibition in triple-negative breast cancer (TNBC). A. Giró-Perafita, S. Palomeras, E. Polonio, J. Ciurana, G. Viñas, **T. Puig** (Girona, Spain) (15')

MOLECULAR ONCOLOGY/CLINICAL ONCOLOGY

Room C, 11:30-13:15
Thursday, October 5

Chair Persons: N.P. Anagnou, M. Koutsaki, K.I. Pappa

284. Cell adhesion and cell-cell signaling are affected by HPV integration, while deregulation of specific pathways occur during the CIN3 to cervical cancer transition. **K.I. Pappa**, A. Polyzos, G. Daskalakis, N.P. Anagnou (Athens, Greece) (30')
218. The miR-200 family in ovarian cancer. **M. Koutsaki**, M. Libra, D.A. Spandidos, A. Zaravinos (Athens; Heraklion, Greece; Catania, Italy; Nicosia, Cyprus) (30')
158. Id-1 siRNA-induced enhancement of chemosensitivity to 5-FU in colorectal cancer SW480 cells. **B. Hu**, H. Yao, Z. Zhu (Hefei, P.R. China) (15')
160. Novel combination of nivolumab and radiotherapy in managing metastatic lung and renal cancers. **J. Ansari**, M. Ali, E. Murshid, A.M. Ali, F. Bashir, A. Farrag, K. Hussein, A.N. Alhamad (Riyadh, Saudi Arabia) (15')
326. Thymidylate synthase 4R polymorphism is a prognostic biomarker in Chinese gastric cancer patients. **J. Chen**, M.H. Wang, R. Men, D. Gu, D. Liang, W.K.K. Wu, K.C. Chong, G. Tam, M.-L. He, B.C.Y. Zee (Nanjing; Hong Kong; Shenzhen; Chengdu; Shijiazhuang, P.R. China) (15')

BIOMARKERS/MOLECULAR ONCOLOGY

Room C, 16:00-17:30
Thursday, October 5

Chair Persons: L. Oliver, V. Bravou

291. Reconstruction of Glioblastoma Multiforme (GBM) using 3D bioprinting. **L. Oliver**, F. Geraldo, F. Vallette (Nantes, France) (25')
230. Integrin-linked kinase, a promising biomarker and therapeutic target in cancer. **V. Bravou** (Patra, Greece) (25')
228. Proteomic analysis of diffuse, localized and non-glioma brain tumors in quest of novel biomarkers. **A.A. Alaiya**, Z. Shinwari, I. Althubaiti, F. Alotaibi, A. Mustafa, H. Alhendi, A. Al Semari (Riyadh, Saudi Arabia) (20')
303. Characterization of polypeptide GalNAc transferase 13 as tumor marker. N. Berois, D. Touya, P. Solari-Saquieres, C. Behrens, R. Alonso, M.F. Festari, O. Pritsch, M. Varangot, I. Wistuba, **E. Osinaga** (Montevideo, Uruguay; Houston, TX, USA) (20')

CHEMOTHERAPY/PHARMACOLOGY

Room C, 18:00-19:30
Thursday, October 5

Chair Persons: B. Köberle, P. Limonta

108. Unraveling the mechanisms of cisplatin-induced nephrotoxicity: effects of cisplatin in renal tubule cells. S. Schoch, P. Schumacher, S. Gajewski, W. Brenner, A. Hartwig, **B. Köberle** (Karlsruhe; Mainz, Germany) (30')
111. Molecular mechanisms of the antitumor activity of δ -tocotrienol in melanoma cells: Endoplasmic reticulum stress and cancer cell stemness. M. Marzagalli, R.M. Moretti, M.M. Marelli, F. Fontana, E. Messi, G. Beretta, **P. Limonta** (Milano, Italy) (30')
226. Patched drug efflux inhibitors enhances chemotherapy efficiency *in vitro* and *in vivo*. A. Hasanovic, C. Ruggiero, M. Volante, C. Hantel, E. Lalli, **I. Mus-Veteau** (Valbonne, France; Munich, Germany; Turin, Italy) (30')

MOLECULAR MEDICINE/PHARMACOLOGY

Room D, 09:00-11:00
Thursday, October 5

Chair Persons: K. Ohlendieck, L. Fang

110. Proteomic identification of serum biomarkers linked to muscular dystrophy. S. Murphy, D. Swandulla, **K. Ohlendieck** (County kildare, Ireland; Bonn, Germany) (30')
112. Diagnostic consequences of cellular motility in solid tumors. L. Pongor, H. Harami-Papp, E. Méhes, A. Czirók, **B. Gyórfy** (Budapest, Hungary; Kansas, KS, USA) (30')
192. Function and regulation of the gp78 ubiquitin E3 ligase. H. Wang, D. Ju, **Y. Xie** (Detroit, MI, USA; Harbin, P.R. China) (30')
320. Interactions between amyloid-beta peptides and human astrocytes calcium-sensing receptors play crucial roles in Alzheimer disease. **I. Dal Prà**, A. Chiarini, U. Armato (Verona, Italy) (30')

MOLECULAR MEDICINE

Room D, 11:30-13:10
Thursday, October 5

Chair Persons: F. Meng, M. Turano

105. Cell mechanics at the molecular level. **F. Sachs**, F. Meng (Buffalo, NY; Bethesda, MD, USA) (30')
222. A new role for human dyskerin in cytoskeletal remodeling and vesicular trafficking. N. Di Maio, R. Vicidomini, A. Angrisani, V. Belli, M. Furia, **M. Turano** (Naples, Italy; Bethesda, MD, USA) (20')
141. Biophysical study of spirochete bacteria as a considerable biological model for targeted drug delivery. **J. Xu**, S. Nakamura, K. Takaba, M.S. Islam, T. Tahara, S. Kudo, E. Isogai (Sendai, Japan; Dhaka, Bangladesh) (20')
199. The role of the BNP genes in Congenital Heart Disease. D. Bobos, **G. Soufla**, I. Morianos, E. Melissari (Athens, Greece) (15')
147. Identification of miRNA variants targeting BRCA genes in familial breast cancer. **T. De Mayo**, A.M. Ziegler, L. Jara (Santiago, Chile) (15')

MOLECULAR MEDICINE

Room D, 16:00-17:30
Thursday, October 5

Chair Persons: P.E. Nielsen, I. Di Liegro

150. Cancer cells can affect behaviour of neighbouring cells by transferring molecules through extracellular vesicles. C.M. Di Liegro, G. Schiera, **I. Di Liegro** (Palermo, Italy) (30')
169. Antisense PNA antibiotics against multiresistant Gram-negative bacteria. **P.E. Nielsen**, F. Björkling, H. Franzyk (Copenhagen, Denmark) (30')
212. Significant changes in renal Bach1 expression in rhabdomyolysis-induced acute kidney injury. **T. Takahashi**, M. Yamaoka, H. Shimizu, H. Moromatsu (Okayama, Japan) (15')
213. Detection of epigenetic biomarkers in tissues and surveillance using saliva samples of head and neck cancer patients. **S. Demokan** (Istanbul, Turkey) (15')

MOLECULAR MEDICINE/SIGNALING

Room D, 18:00-19:30
Thursday, October 5

Chair Persons: M.K. Gill, C. Bernabeu

178. Elucidating the role of a novel hippo inhibitory kinase in modulating the hippo pathway in cancer. **M.K. Gill**, Y. Zhang, T. Christova, M. Narimatsu, A. Gregorieff, L. Zhang, S. Song, S. Xiong, F. Sicheri, J.L. Wrana, L. Attisano (Toronto, Canada) (25')
280. Emerging role of endothelial endoglin in integrin-mediated cell adhesion. **C. Bernabeu** (Madrid, Spain) (20')
225. Tumor necrosis factor alpha induces mechanical breakdown of endothelial cell-cell junctions through F-actin-dependent changes in cell shape and increased focal adhesion. **M. Gagat**, D. Grzanka, A. Krajewski, M. Halas-Wisniewska, M. Izdebska, A. Grzanka (Bydgoszcz, Poland) (25')
297. Arl13b promotes gastric tumorigenesis by regulating Smo trafficking and activation of the Hedgehog signaling pathway. J. Shao, L. Xu, L. Chen, Q. Lu, X. Xi, W. Shi, H. Xiong, C. Shi, X. Huang, J. Mei, H. Rao, H. Lu, N. Lu, **S. Luo** (Nanchang, P.R. China; San Antonio, TX; New Orleans, LA, USA) (20')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Friday, October 6

Chair Persons: P.S. Rennie, T.L. Rižner

101. Using computer-aided drug design to discover and create new anti-androgens to treat castration-resistant prostate cancers. K. Dalal, E. Leblanc, N. Lallous, F. Ban, A. Cherkasov, **P.S. Rennie** (Vancouver, Canada) (30')
299. The importance of OATP, OAT and ABC transporters for estrogen formation in endometrial cancer. R. Pavlič, C. Laczka, M. Anko, **T.L. Rižner** (Ljubljana, Slovenia; Budapest, Hungary) (30')
125. The efficacy of preoperative chemoradiotherapy in patients with gastric and rectal cancer. **I. Jung**, L. Baniias, C. Molnar, V. Butiurca, S. Gurzu (Tirgu-Mures, Romania) (30')
288. Post-surgery fluids promote transition of cancer stem cells to endothelial cells and increase AKT/mTOR activity, contributing to the relapse of giant cell tumors of the bone. **F. De Nigris**, F. Fazioli, G. Colella, R. Miceli, M.G. Di Salvatore, M. Gallo, S. Boccella, A. De Chiara, C. Ruosi (Naples Italy) (30')

BREAST CANCER

Room A, 11:30-13:00
Friday, October 6

Chair Persons: D. Marchetti, I. Barash

102. Molecular characterization of breast cancer CTCs associated with brain metastasis. D. Boral, M. Vishnoi, H.N. Liu, W. Yin, M.L. Sprouse, A. Scamardo, D.S. Hong, T.Z. Tan, J.P. Thiery, J.C. Chang, **D. Marchetti** (Houston, TX, USA; Singapore) (30')
145. De-regulated Stat5 activity in individual epithelial cells during parity cycles may represent a risk factor for latent breast cancer development. M. Reichenstein, G. Rauner, T. Kudinov, S. Kfir, T. Kisliouk, **I. Barash** (Bet-Dagan; Jerusalem, Israel) (30')
142. Designing strategies to target IL13Ra2-mediated breast cancer metastasis. M. Kalli, C.M. Neophytou, A. Constantinou, **P. Papageorgis** (Nicosia, Cyprus) (30')

SIGNALING PATHWAYS

Room A, 16:00-17:30
Friday, October 6

Chair Persons: M. Krstic-Demonacos, C. Demonacos

233. TTC5 cofactor of nuclear hormone receptors. F. Ashtiani, M. Sadeq, W. Almusrati, E. Isogai, K. Kuroda, L. Mutti, C. Demonacos, **M. Krstic-Demonacos** (Salford; Manchester UK; Sendai, Japan) (30')
234. Regulation of autophagy, endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in acute lymphoblastic leukemia (ALL) cells by glucocorticoids. S. Sudsaward, S. Khunchai, R. Rajendran, L. Mutti, T. Limjindaporn, P.-T. Yenchitsomanus, M. Krstic-Demonacos, **C. Demonacos** (Salford; Manchester UK; Phitsanulok; Bangkok, Thailand; Kuala Lumpur, Malaysia) (30')
134. Elucidation of the signaling pathways that mediate TRAIL combination-induced apoptosis in cancer cells. R. Ke, K. Vishnoi, N. Viswakarma, S. Das, A. Rana, **B. Rana** (Chicago, IL, USA) (30')

THERAPEUTICS/TUMOR MICROENVIRONMENT

Room A, 18:00-19:30
Friday, October 6

Chair Persons: D.E. Johnson, L. Vannucci

154. The mutational profile of head and neck cancer: Opportunities for therapy and chemoprevention. J.R. Grandis, T.M. Brand, N.E. Bholra, H. Li, B.C. Leonard, **D.E. Johnson** (San Francisco, CA, USA) (30')
235. Gadolinium-based nanoparticles for targeting the tumor microenvironment. **L. Vannucci**, L. Rajsiglová, D. Stakheev, D. Lehutova, V. Havliček, D. Luptaková, T. Pluhacek, P. Ceci, E. Falvo, M. Babic, U. Kostiv, D. Horak, J. Krizan, J. Vrba, J. Vrba Jr, D. Vrba, L. Farina, V. Lopresto, G. Ruvio, P. Makovicky, P. Makovicky, R. Sedlacek (Prague, Vestec, Czech Republic; Rome, Italy; Galway, Ireland; Komarno, Slovak Republic) (30')
106. How does pancreatic cancer re-program the tumor microenvironment? **L. Zheng** (Baltimore, MD, USA) (30')

WORKSHOP ON INFLAMMATION AND DISEASES: CARDIOVASCULAR DISEASES

Organized by **S.S. Signorelli**

Room B, 09:00-11:00

Friday, October 6

Chair Persons: S.S. Signorelli, J. Lurins

- 270. A man is just as old as his arteries: Crosstalk between biomarkers and arterial stiffness. **V. Bona** (Bergamo, Italy) (20')
- 269. Biomarkers for thrombotic venous disease: Useful tool in decision making. **G. Lessiani** (Pescara, Italy) (20')
- 272. Atherosclerosis and osteoporosis: Two sides of the same coin? **A. Gaudio** (Catania, Italy) (20')
- 275. Chronic arterial ischemia: Inflammatory biomarkers, oxidative stress and epigenetic. **S.S. Signorelli** (Catania, Italy) (20')
- 273. Impact of several proinflammatory and degeneration factors in aortic valve stenosis. **J. Lurins**, D. Lurina, P. Tretjakovs, V. Mackevics, A. Lejnieks, V. Rapisarda, V. Baylon (Jelgava; Riga, Latvia; Catania, Italy; Saint John, Malta) (20')
- 274. Inflammatory biomarkers and myocardial damage in patients with coronary artery bypass surgery. **S. Jovev**, S. Mitrovska, V. Baylon (Skopje, FYROM; Saint John, Malta) (20')

MOLECULAR MEDICINE

Room B, 11:30-13:00

Friday, October 6

Chair Person: M. Ferrante, P. Fagone

- 271. Gene-environment interaction and neurodegenerative diseases. G. Oliveri Conti, M. Fiore, **M. Ferrante** (Catania, Italy) (30')
- 285. Identification of sex-dependent and -independent DNA methylation mediators in rheumatoid arthritis. **P. Fagone**, K. Mangano, S. Mammana, E. Cavalli, M.S. Basile, F. Nicoletti (Catania, Italy) (30')
- 286. Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis. S. Mammana, P. Fagone, E. Cavalli, M.S. Basile, M.C. Petralia, F. Nicoletti, **K. Mangano** (Catania, Italy) (15')
- 277. Concomitant Mycobacterium tuberculosis infection promotes lung tumor growth through enhancing Treg development. **Y. Zhou** (Shanghai, P.R. China) (15')

GYNECOLOGICAL CANCER/THERAPEUTICS

Room B, 16:00-17:30
Friday, October 6

Chair Persons: H.-J. Kim, M. Zhang

136. Discoveries of cytological and serological biomarkers for new primary screening system of cervical cancer. **H.-J. Kim**, S.C. Kim, Y. Jin, H.J. Kim, W. Ju, Y.H. Kim (Seoul, Republic of Korea) (25')
248. MiR-22 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. **M. Zhang** (Kunming, P.R. China) (25')
217. Effects of various estrogen ligands on the structural conformation of human estrogen receptor α . X. Chen, **U. Uzuner**, M. Li, W. Shi, J.S. Yuan, S.Y. Dai (College Station, TX, USA; Trabzon, Turkey) (20')
232. Secreted tumor suppressor Ecr4 acts as a novel immunosurveillance factor. T. Moriguchi, S. Takeda, U. Koshimizu, H. Kitamura, **T. Kondo** (Sapporo, Japan) (20')

MOLECULAR ONCOLOGY/microRNAs

Room B, 18:00-19:30
Friday, October 6

Chair Persons: G. Sourvinos, E. Rizos

282. The challenge of microRNAs as potential diagnostic biomarkers and therapeutic tools of viral infections. **G. Sourvinos** (Heraklion, Greece) (20')
315. Could schizophrenia be a protective factor against cancer? The possible role of microRNAs on this hypothesis. **E. Rizos**, N. Siafakas, E. Skourti, C. Papageorgiou, J. Tsoporis, Th. Parker, D.A. Spandidos, E. Katsantoni, V. Zoumpourlis (Athens; Heraklion, Greece; Toronto, Canada) (20')
114. Implication of microRNA signatures and Foxp3+ cells in the relapse of follicular lymphoma patients. **G. Malpeli** (Verona, Italy) (20')
121. Insight into the genetics of embryonal rhabdomyosarcoma. **A. Ahmed** (Kansas, MO, USA) (15')
129. The diagnostic value of serum miRNAs and preoperative prediction of tumor subtype in patients with early-stage non-small cell lung cancer. **W.-Y. Zhu**, K.-X. Fang, H.-B. Le, Y.-K. Zhang (Zhoushan, P.R. China) (15')

MOLECULAR ONCOLOGY/THERAPEUTICS

Room C, 09:00-11:00

Friday, October 6

Chair Persons: M. Gottardi, T. Nakamura

180. Emerging role of vascular modulator peptides in hematologic malignancies. R. Di Liddo, C. Tecchio, A. Piccin, M.T. Conconi, F. Gherlinzoni, **M. Gottardi** (Padova; Verona; South Tyrol; Treviso, Italy) (25')
208. The p53 suppression on tumor cells may suppress an innate immunity by modulating the function of recruited macrophages. **T. Nakamura** (Kurashiki, Japan) (25')
294. IL-18 primes murine NK cells for proliferation. **Y. El-Darawish**, W. Li, K. Yamanishi, H. Yamanishi, H. Okamura (Nishinomiya; Osaka, Japan) (25')
201. The role of microenvironment in progression from *in situ* to invasive breast cancer: New insights to prevention strategies. **M. Figueiredo Dias** (Coimbra, Portugal) (25')
309. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. **M. Rusan**, K. Li, Y. Li, C.L. Christensen, B.J. Abraham, N. Kwiatkowski, K.A. Buczkowski, B. Bockorny, T. Chen, S. Li, K. Rhee, H. Zhang, W. Chen, H. Terai, T. Tavares, T. Zhang, T.J. Kim, S. Hong, N. Poudel Neupane, M. Silkes, T. Mudianto, L. Tan, T. Shimamura, M. Meyerson, A.J. Bass, H. Watanabe, N.S. Gray, R.A. Young, K.K. Wong, P.S. Hammerman (Boston, MA; Cambridge, MA; Chicago, IL; New York, NY, USA; Aarhus, Denmark; Seoul, Republic of Korea; Shanghai, P.R. China) (20')

MOLECULAR ONCOLOGY/LUNG CANCER

Room C, 11:30-13:00

Friday, October 6

Chair Persons: S. Qin, H. Okamura

209. The use of Smac in the diagnosis and treatment of lung cancer. **S. Qin**, C. Yang, B. Zhang, G. Xiao, X. Li, X. Sun, C. Hu, H. Ren (Xi'an, P.R. China) (30')
295. Effect of IL-18 on anti-tumor action of IDO inhibitor in mouse models. W. Li, Y. El-Darawish, K. Yamanishi, H. Yamanishi, **H. Okamura** (Nishinomiya; Osaka, Japan) (30')
124. Integrated analysis of competing endogenous RNA network to reveal potential long non-coding RNA biomarkers in human lung squamous cell carcinoma. Y. Miao, J. Sui, L. Yin, Y. Pu, **G. Liang** (Nanjing, P.R. China) (30')

MOLECULAR ONCOLOGY/COLON CANCER

Room C, 16:00-17:30
Friday, October 6

Chair Persons: A.K. Larsen, S. Savas, M. De Rosa

314. Acquired drug resistance is accompanied by pro-invasive autocrine and paracrine signaling networks in colorectal cancer models. **A.K. Larsen**, M. Kolski, P. van Dreden, G.T. Gerotziafas, S. Thouroude (Paris, France) (20')
135. Examining genetic variations and survival outcomes in colorectal cancer patients: A summary of our past research and future directions. **S. Savas** (St. John's, Canada) (20')
227. Effects of GSK3beta inhibition on motility and plasticity of colorectal cancer cells. V. Costabile, M. Turano, F. Duraturo, P. Delrio, D. Rega, U. Pace, G.B. Rossi, M. Milone, C. Dodaro, P. Izzo, **M. De Rosa** (Naples, Italy) (20')
182. Immune cytolytic activity is correlated with distinct mutational events in colorectal cancer. **A. Zaravinos**, K. Roufas, C. Efstathiades, C. Dimopoulos (Nicosia, Cyprus) (15')
185. Molecular mechanisms underlying resistance to MEK1 inhibition in colorectal cancer. **H.-Q. Duong**, S. Delaunay, P. Close, K. Shostak, A. Chariot (Liege, Belgium; Hanoi, Vietnam) (15')

MOLECULAR ONCOLOGY

Room C, 18:00-19:30
Friday, October 6

Chair Persons: A. Amedei, W. Song

198. The role of adaptive immune response in gastrointestinal oncology. **A. Amedei** (Florence, Italy) (15')
193. lncRNA-a7 is upregulated by HBx and functions as a scaffold to suppress CDH1 expression by recruiting G9A/SNAI1 for HCC metastasis. **W. Song**, H. Wu, J. Hu, Z. Cheng, S. Lu, H. Fan (Nanjing, P.R. China) (15')
194. UCA1-miR-203-ZEB2 axis contributes to epithelial-mesenchymal transition and cell migration in gastric cancer. **P. Gong**, F. Qiao, H. Wu, K. Zhang, H. Fan (Nanjing; Harbin, P.R. China) (15')
187. Effects of HBV and anti-HBV drug Entecavir on the expression of circadian clock genes in human hepatocellular carcinoma cells. **S.-L. Yang**, X.-M. Dai, J.-L. Hu, T. Zhang, Q.-S. Wang (Wuhan, P.R. China) (15')
283. Thymidylate phosphorylase mRNA level is an independent marker of prognosis in local and advanced colon cancer patients. **A. Babenka**, K. Ruksha, S. Smirnov, I. Anufreyonak, D. Mikhniuk, V. Kohniuk, A. Portyanko (Lesnoy, Belarus) (15')
181. Mitochondrial and nuclear DNA methylation profiles of metastatic cancer cells. **S. Çelik-Uzuner** (Trabzon, Turkey) (15')

PROSTATE CANCER

Room A, 09:00-11:00
Saturday, October 7

Chair Persons: N.A. Franken, R.J. Rosengren

107. Reduced expression of homologous recombination DNA repair genes in prostate cancer patients with late radiation toxicity. B. van Oorschot, L.J. Stalpers, **N.A. Franken** (Amsterdam, The Netherlands) (25')
146. Raloxifene decreases metastasis in an orthotopic model of hormone refractory prostate cancer. H. Palmer, M. Nimick, **R.J. Rosengren** (Dunedin, New Zealand) (25')
179. Ultrasonographic monitoring of rat prostate cancer development. **M. Ginja**, M. Fardilha, R. Ferreira, P.A. Oliveira, E. Nascimento-Gonçalves, A.I. Faustino-Rocha (Vila Real; Aveiro; Lisbon, Portugal) (25')
196. The influence of physical exercise in rat prostate cancer development. **P.A. Oliveira**, R. Ferreira, M. Fardilha, M. Ginja, A.I. Faustino-Rocha (Vila Real; Aveiro; Lisbon, Portugal) (25')
312. Role of stemness genes on metastasis progression in prostate cancer. **E.A. Castellón**, R. Valenzuela, F. Cifuentes, T. Thomson, H.R. Contreras (Santiago, Chile; Barcelona, Spain) (20')

THERAPEUTICS

Room A, 11:30-13:00
Saturday, October 7

Chair Persons: S.M. Hyder, G.T. Gerotziafas, J.K. Cowell

203. Luteolin inhibits growth and metastasis of human breast cancer cells. **S.M. Hyder** (Columbia, MO, USA) (30')
276. Cancer cells alter the procoagulant potential of the endothelium through emission of microparticles. A new mechanism of the pathogenesis of cancer associated thrombosis. R. Amrane, A. Rousseau, P. van Dreden, A. Larsen, I. Elalamy, **G.T. Gerotziafas** (Paris, France) (30')
293. Targeting the WASF3 regulatory complex to suppress metastasis. **J.K. Cowell**, Y. Teng, A.S. Arbab, E.J. Kennedy (Augusta; Athens, USA) (30')

3RD WORKSHOP ON PAEDIATRIC VIROLOGY
Organized by the **Paediatric Virology Study Group**

Room A, 16:00-17:30
Saturday, October 7

Chair Persons: A. Kramvis, A. Greenough

237. Mother to child transmission of hepatitis B and C viruses. **A. Kramvis** (Johannesburg, South Africa) (20')
238. Foetal and neonatal brain imaging in viral infections. **G. Papaioannou** (Athens, Greece) (20')
239. Probiotics and viral infections in childhood. **P. Korovessi** (Athens, Greece) (15')
240. Intranasal live-attenuated influenza vaccination in children: Evidence, limitations and proposals. **A. Melidou** (Thessaloniki, Greece) (15')
241. RSV and rhinovirus infection in early childhood and their role in asthma. **C. Koutsaftiki** (Athens, Greece) (10')
242. Viral infections of central nervous system in children. **A.E. Papatheodoropoulou** (Athens, Greece) (10')

3RD WORKSHOP ON PAEDIATRIC VIROLOGY
Organized by the **Paediatric Virology Study Group**

Room A, 18:00-19:30
Saturday, October 7

Chair Persons: H. zur Hausen, D.A. Spandidos

243. The causes and contexts of perinatal mortality in ancient Greece: A case study from the 'bone well' of the Athenian agora. **M.A. Liston** (Waterloo, Canada) (15')
244. Human papillomavirus infections in children: Should we be vaccinating earlier? **M. Rusan** (Boston M.A., USA; Aarhus, Denmark) (10')
245. The long term impact of viral infections on prematurely born infants. **A. Greenough**, V. MacBean, A. Lunt, S.B. Drysdale, G.F. Rafferty, J.L. Peacock (London, UK) (20')
247. Paediatric virology and oncology: Virus persistence and the important first years of life. **H. zur Hausen** (Heidelberg, Germany) (45')

WORKSHOP ON INFLAMMATION AND DISEASES: DEGENERATIVE CHRONIC DISEASES

Organized by **S.S. Signorelli**

Room B, 09:00-11:00

Saturday, October 7

Chair Persons: M. Libra, V. Rapisarda, C. Fenga

257. Immunoexpression and localization of heme-oxygenase-1 and MIF in lung exposed to asbestos-like fibers: an *in vivo* study. **R. Caltabiano**, C. Loreto, S. Castorina, C. Lombardo, P. Fagone, F. Nicoletti, P. Senia, C. Ledda, V. Rapisarda (Catania, Italy) (20')
258. MMP-9 overexpression as a result of MMP9 intragenic hypermethylation. **S. Candido**, R. Salemi, L. Falzone, G. Malaponte, A. Scalisi, M. Libra (Catania, Italy) (20')
259. Immunotoxicity of pesticides: Potential health effects on exposed subjects. C. Costa, M. Teodoro, E. Miozzi, G. Briguglio, **C. Fenga** (Messina, Italy) (20')
260. Cytokine patterns in workers occupational exposed to wood dust. **C. Ledda**, V. Rapisarda, S. Cocuzza, E. Miozzi, C. Costa, C. Fenga (Catania; Messina, Italy) (20')
261. Diet and inflammation in cancer: From pathogenesis to therapy. **M. Libra**, F. Nicoletti, L. Augustin, L. Falzone, M. Montella (Catania; Naples, Italy) (20')
262. Hematological and biochemical modifications after occupational exposure to pesticides. V. Rapisarda, **E. Miozzi**, A. Marconi, S. Matera, G. Romano, L. Fago, D. Cinà, C. Ledda (Catania, Italy) (20')

BRAIN TUMORS/CLINICAL ONCOLOGY

Room B, 11:30-13:00

Saturday, October 7

Chair Persons: K. Malik, H.M. Said

236. Novel targets for neuroblastoma therapeutics. J.H. Park, M. Szemes, M. Kollareddy, K. Gallacher, Z. Dixon, **K. Malik** (Bristol, UK) (30')
254. Modulation of the NDRG1 gene expression in a time and oxygen concentration dependent manner in human brain cancer cells. **H.M. Said**, G. Al-Kafaji, R. Safari, D. Harmanci, Y. Soysal, A. Kocak, F.D. Ince, R. Ernestus, M. Löhr, C. Hagemann (Izmir, Turkey; Manama, Kingdom of Bahrain; Würzburg, Germany) (30')
168. Prognostic value of the CPS+EG staging system and Neobio score after neoadjuvant chemotherapy for locally advanced breast cancer. **M. Ali**, A. Farrag, E. Murshid, J. Ansari, M. Wahid, A.M. Ali, A.N. Alhamad, K. Al Hajri, R.E. Murshid (Riyadh, Saudi Arabia; Assiut, Egypt) (15')
221. MiR-139-5p is a regulator of cell growth pathways in pediatric low-grade gliomas. **G. Catanzaro**, Z.M. Besharat, E. Miele, A. Po, M. Chiacchiarini, L. Abballe, R. Gariazzo, V. Alfano, M. Antonelli, F. Giangaspero, A. Carai, C.E. Marras, F. Locatelli, A. Mastronuzzi, E. Ferretti (Rome; Pavia, Italy) (15')

TUMOR BIOLOGY/CARCINOGENESIS

Room B, 16:00-17:30
Saturday, October 7

Chair Persons: H. Tuncel, S. Gurzu

128. Physical view on cancer: Assessment of cellular mechanical and electrical properties. **H. Tuncel** (Istanbul, Turkey) (20')
126. Pitfalls in evaluation of gastrointestinal specimens: Metastases mimicking primary tumors. **S. Gurzu**, S. Mocan, L. Baniias, T. Bara, T. Bara Jr, I. Jung (Tirgu-Mures, Romania) (20')
255. Regulation of heparansulfate biosynthesis by transcriptional factors in various human tissues. **A.V. Suhovskih**, V.S. Ushakov, V.I. Kashuba, E.V. Grigorieva (Novosibirsk, Russia; Stockholm, Sweden) (20')
116. Opposite effects of TPD52 and TPD54 on oral squamous cell carcinoma cells. **Y. Mukudai**, K. Kato, H. Motohashi, C. Ito, S. Kamoshida, T. Shimane, S. Kondo, T. Shiota (Tokyo; Fukuoka, Japan) (15')
195. Serotonin altered receptor tyrosine signalling pathway differently in MCF-7 and MDA-MB-231 breast cancer cells. **E.D. Arisan**, D. İlkan, P. Ozfiliz Kilbas, A. Coker Gurkan, P. Obakan Yerlikaya, N. Palavan Unsal (Istanbul, Turkey) (15')

MOLECULAR ONCOLOGY/THYROID CANCER

Room C, 09:00-11:00
Saturday, October 7

Chair Persons: M. Acevedo-Duncan, A. Antonelli

127. Atypical protein kinase C inhibitors can repress epithelial to mesenchymal transition (type III) in malignant melanoma. W.S. Ratnayake, **M. Acevedo-Duncan** (Tampa, FL, USA) (25')
207. Sunitinib in thyroid cancer. **A. Antonelli**, S.M. Ferrari, P. Fallahi (Pisa, Italy) (25')
205. Lenvatinib in thyroid cancer. **S.M. Ferrari**, P. Fallahi, A. Antonelli (Pisa, Italy) (20')
206. Radiation exposure and thyroid cancer. **P. Fallahi**, S.M. Ferrari, A. Antonelli (Pisa, Italy) (20')
163. Systemic treatment in rare lacrimal gland carcinoma. **F. Xia**, H. Xu, X. Ma (Chengdu, P.R. China) (15')
268. Retrospectively analyze 36 fusion genes in 6170 patients of de novo acute leukemia and myeloid neoplasms. X. Chen, **D. Nie**, F. Wang, Y. Zhang, M. Wang, W. Teng, X. Ma, L. Guo, J. Fang, Y. Zhang, P. Zhu, H. Liu (Langfang; Beijing, P.R. China) (15')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room C, 11:30-13:10
Saturday, October 7

Chair Persons: B. Zhou, A. Rana

149. Mechanism based repurposing of neurodegenerative disease drugs for breast cancer treatment. R.S. Nair, S. Das, G. Sondarva, N. Viswakarma, K. Fuller, L. Ibrahim, B. Rana, **A. Rana** (Chicago, IL, USA) (20')
130. Hypertension and adrenal tumor. **B. Zhou** (Hefei, P.R. China) (20')
249. Molecular and immunological indicators of biological malignancy in urothelial bladder cancer. W. Józwicki, **D. Grzanka**, A.A. Brożyna (Bydgoszcz, Poland) (15')
231. Bag-1 silencing enhanced apoptosis via altering the ubiquitination process of Foxo3a in MCF-7 breast cancer cells. **P.O. Kilbas**, E.D. Arisan, G.D. Doganay, N.P. Unsal (Istanbul, Turkey) (15')
306. Silent breast cancer: A pilot study of the disease prevalence held by imaging guided biopsies in autopsy specimens (SISYPHUS). **Z. Sidiropoulou**, A. Vasconcelos, C. Couceiro, A. Araújo, I. Alegre, C. Santos, F. Costa, C. Santos, V. Henriques, C. Neves, F. Cardoso, P. Gascón (Lisbon, Portugal; Barcelona; Catalonia, Spain) (15')
321. Mutations in mtDNA in breast cancer. **L. Grzybowska-Szatkowska**, J. Rzymowska, B. Ślaska (Lublin, Poland) (25')

Chair Persons: N. Telang, L.M. Junie

210. Carbapenem resistance in the *Klebsiella pneumoniae* strains, detected by phenotypic and molecular methods. M. Tompa, S.L. Pandrea, M.I. Ciontea, E. Chiorean, **L.M. Junie** (Cluj-Napoca, Romania) (25')
117. Cellular model for cancer stem cells from genetically predisposed familial adenomatous polyposis (FAP) syndrome. **N. Telang** (Montvale, NJ, USA) (25')
123. MiR-26a reduces bladder cancer cell proliferation and induces apoptosis by directly suppressing the expression of EZH2. B. Zhou, E. Wei, H. Shi, J. Huang, L. Gao, T. Zhang, Y. Wei, **B. Ge** (Guilin, P.R. China) (20')
289. Evidences for anti-oxidant and anti-inflammatory activities of a flavonoid-rich extract from orange juice. S. Cirmi, N. Ferlazzo, A. Maugeri, G.E. Lombardo, **M. Navarra** (Messina, Italy) (20')

POSTERS (Poster viewing during the entire congress)

109. Thymoquinone induces degradation of UHRF1 via auto-ubiquitinylation: A key event for tumor suppressor gene upregulation. A. Ibrahim, M. Alhosin, C. Papin, K. Ouararhni, R.M. Alghamdi, Z. Omran, M.A. Zamzami, H. Choudhry, Y. Mely, A. Hamiche, M. Mousli, **C. Bronner** (Strasbourg, France; Jeddah; Makkah, Saudi Arabia)
119. Association of STD pathogens via multiplex PCR detection. **M.L. Vică**, L.M. Junie, H.V. Matei (Cluj-Napoca, Romania)
120. Comparative study of the HLA alleles' frequencies in Romania and Europe. **H.V. Matei**, C. Siserman, M.E. Cîmpianu, M.L. Vică (Cluj-Napoca, Romania)
131. Resveratrol counteracts the pro-invasive activity of lysophosphatidic acid in ovarian cancer cells by rescuing autophagy: Involvement of the Hedgehog pathway. **A. Ferraresi**, C. Seca, A. Castiglioni, S. Thongchot, D.N. Dhanasekaran, C. Isidoro (Novara, Italy; Oklahoma, OK, USA)
132. Detection of human norovirus replication in cell culture by Mab's to common calicivirus epitope. **V. Sologub**, I. Koromyslova, U. Belousova, A. Muchin (Moscow, Russia; Turku, Finland)
138. YKL-40, TCN1, GUCA2B and CA7: A possible gene expression signature in colorectal cancer. **Y. Feodorova**, G. Kostov, A. Todorov, K. Simitchiev, I. Koev, D. Tashkova, V. Belovejdov, R. Dimov, V. Sarafian (Plovdiv, Bulgaria)
139. A dual approach for identification of new miRNA biomarkers in oral squamous cell carcinoma. **N. Mehterov**, K. Tonchev, B. Vladimirov, V. Sarafian (Plovdiv, Bulgaria)
140. Analysis of exosomes released by colon cancer cells after treatment with the antimicrobial peptide FF/CAP18. M. Hayashi, K. Kuroda, M.K. Demonacos, C. Demonacos, T. Iwaya, Y. Matsumoto, H. Isogai, **E. Isogai** (Tohoku; Tokyo; Sapporo, Japan; Salford; Manchester, UK)
148. Metformin prevents NGF-dependent proliferative and pro-angiogenic effects in epithelial ovarian cancer and endothelial cells. **M. Garrido**, M. Vega, A. Quest, C. Romero (Santiago, Chile)
152. Identification of novel variations in microRNAs genes as familial breast cancer susceptibility variants in the Chilean population. **N. Landeros**, J. Tapia, P. Gonzalez-Hormazabal, L. Jara (Santiago, Chile)
153. Association of single nucleotide polymorphisms in pre-miR-423 and pre-miR-27a with breast cancer susceptibility: Evidence from clinical and functional studies. **S. Morales**, R. Fernández-Ramires, J. Tapia, L. Jara (Santiago, Chile)
157. Resveratrol contrasts ovarian cancer cell migration induced by interleukin-6: Role of glucose metabolism and autophagy. **A. Ferraresi**, C. Vidoni, S. Phadngam, A. Castiglioni, A. Galetto, G. Chiorino, C. Isidoro (Novara; Biella, Italy)
159. Malignant duodenocolic fistula: A rare case report and literature review. **B. Hu**, X. He, Z. Zhu (Hefei, P.R. China)
161. Multifactor-dimensionality reduction reveals interaction among MRE11 and clinicopathologic factors on breast cancer recurrence. **S.-H. Moi**, Y.-H. Chen, F. Ou-Yang, M.-F. Hou, C.-H. Yang (Kaohsiung, Taiwan, R.O.C.)
162. A 3-year cohort study on short-term treatment effects of IORT and EBRT in early breast cancer patients. **Y.-H. Chen**, S.-H. Moi, F. Ou-Yang, M.-F. Hou, F.-M. Chen (Kaohsiung, Taiwan, R.O.C.)
164. A case of malignant fibrous histiocytoma of giant cell subtype in an animal model. H. Vala, L. Andrade, F. Esteves, C. Santos, **P.A. Oliveira**, R. Cruz, A.C. Mega, J.R. Mesquita, A. Gomes, C. Nóbrega (Viseu; Vila Real, Portugal)
165. A spontaneous Zimbal gland tumor in a Wistar male rat. M. Rodrigues-Ribeiro, A.I. Faustino-Rocha, M. Correia-Cardoso, C.N. Fonseca, M.S.S. Moutinho, R. Ferreira, M. Fardilha, F. Seixas, **P.A. Oliveira** (Vila Real; Lisbon; Aveiro, Portugal)
166. The anti-cancer effect of Bromo-amine T (BAT). **S. Baliou**, M. Nagl, A.M. Kyriakopoulos, V. Zoumpourlis (Athens; Pireas Greece; Innsbruck, Austria)
167. Mesenchymal stem cells for cancer cytotherapy: Challenges and novel approaches. M. Devetzi, **M. Goulielmaki**, I. Christodoulou, V. Zoumpourlis (Athens, Greece)
170. Inhibition of S100B-p53^{wt} interaction by pentamidine counteracts carcinogenic drift in human colon cancer. **S. Gigli**, L. Seguella, M. Pesce, L. Steardo, G. Sarnelli, G. Esposito (Rome; Naples, Italy)

173. Delivery of miRNA-targeted oligonucleotides in the rat striatum by magnetofection with Neuromag®. **C.H. Horst**, S.S. Titz-de-Almeida, F. Schlemmer, A.C.M. Domingues, P.H.S. Costa, E.A. Del Bel Guimarães, C. Soto-Sanches, E. Fernández, R. Titz-de-Almeida (Brasília; São Paulo, Brazil; Elche, Spain)
175. Classical prognostic features are not enough to predict clinical behavior of *in situ* breast cancer. I. Ramalho, A. Rolha, A.S. Pais, **M. Figueiredo Dias** (Coimbra, Portugal)
176. Incremental value of diffusion weighted MRI as an early predictor of treatment response of neoadjuvant chemotherapy in breast cancer. M.A. Gonçalves, L. Curvo-Semedo, **M. Figueiredo Dias** (Coimbra, Portugal)
183. Immune cytolytic activity across various cancer types. **A. Zaravinos**, K. Roufas, C. Efstathiades, C. Dimopoulos (Nicosia, Cyprus)
184. Paediatric virology: Focusing on medical education and training research. **I.N. Mammias**, D.A. Spandidos (Heraklion, Greece)
191. Promoter methylation profile of circadian genes in breast cancer. **M. Przybek**, E. Jablonska, E. Wiczorek, L. Kalinowski, J. Skokowski, B. Seroczynska, W. Wasowicz, E. Reszka (Lodz; Gdansk, Poland)
197. Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in gastric cancer. J. Park, H.M. Yoo, S. Shin, **J.G. Kim** (Seoul, Republic of Korea)
200. Effects of moderate long-term exercise training on mammary cancer vascularization: Contrast-enhanced ultrasound. A.I. Faustino-Rocha, **P.A. Oliveira**, A. Gama, R. Ferreira, M. Ginja (Vila Real; Lisbon; Aveiro, Portugal)
202. Functional characterization of specific immune response and comparison of oral and intestinal human microbiota in patients with colorectal cancer after treatment with probiotic/prebiotic. E. Russo, G. Bacci, E. Niccolai, A. Taddei, F. Ricci, M.N. Ringressi, C. Chiellini, C. Fagorzi, P. Bechi, A. Mengoni, R. Fani, **A. Amedei** (Florence, Italy)
204. Heterogeneity of triple-negative breast cancer: Prognostic significance of MR imaging features according to molecular subtypes. **S.U. Shin** (Seoul, Republic of Korea)
211. Targeting castration-resistant prostate cancer cells with nutraceutical compounds: The antitumor activity of δ -tocotrienol. F. Fontana, M.M. Marelli, R.M. Moretti, M. Marzagalli, **P. Limonta** (Milano, Italy)
214. Investigation of the new epigenetic biomarkers in oral cavity malignant lesions by methylation arrays. **S. Demokan**, S. Comert, O. Eryilmaz, S. Sen, M. Uluhan, G. Ak, C. Alatli, N. Dalay (Istanbul, Turkey)
224. NF- κ B contributes to the proliferation and migration of ovarian cancer cells by regulating mortalin. **W. Liu**, S. Li, L. Yang, J. Zuo (Shanghai, P.R. China)
229. Focal adhesion proteins are implicated in KRAS driven lung carcinogenesis. S. Nikou, C. Geramoutsou, M. Makrygianni, V. Zolota, G.T. Stathopoulos, H. Papadaki, **V. Bravou** (Patras, Greece)
246. Immigration crisis and vaccination policy. **M. Theodoridou** (Athens, Greece)
250. Evaluation of anti-metastatic potential of the combinations of fisetin with paclitaxel or arsenic trioxide on A549 cells. A. Klimaszewska-Wisniewska, M. Halas-Wisniewska, A. Grzanka, **D. Grzanka** (Bydgoszcz, Poland)
251. Malignant mesothelioma: A case of the rare primary tumor of the spermatic cord. A. Kasperska, I. Neska-Długosz, E. Domanowska, **D. Grzanka** (Bydgoszcz, Poland)
252. Influence of Quercetin on cytoskeleton-dependent adhesion and cell death of A549 non-small cell lung carcinoma cells under controlled SATB1 expression. M. Gagat, **M. KostECKa**, M. Hałas-Wisniewska, M. Izdebska, D. Grzanka (Bydgoszcz, Poland)
263. A 72-year-old male patient with adenocarcinoma in duodenal papilla underwent Whipple's operation. Report of an interesting case. **G.I. Panagiotakis**, S. Xenaki, M. Venianaki, A. Gavalaki, D. Sekadakis, E. Athanasakis, I.E. Petrakis, M. Tzardi, E. Chrysos, G.E. Chalkiadakis (Heraklion, Greece)
265. Integrated strategy of differentially expressed genes associated with ulcerative colitis. **J. Feng**, Q. Gao, Q. Liu, F. Wang, X. Lin, Q. Zhao, J. Liu, J. Li (Wuhan, P.R. China)

278. Intracellular content of doxorubicin conjugated with 4th generation dendrimers and vector protein in breast cancer cells with different chemosensitivity. **O. Matchuk**, K. Churyukina, N. Yabbarov, E. Nikolskaya, I. Zamulaeva (Obninsk, Russia)
279. Cytotoxic effects of doxorubicin conjugates with dendritic polymers of second and forth generations on breast cancer cells *in vitro*. **I. Zamulaeva**, K. Churyukina, O. Matchuk, S. Makarenko, E. Nikolskaya, N. Yabbarov (Obninsk, Russia)
281. How can EBV be regulated in cancer diseases. **G. Glady** (Colmar, France)
287. Chlorogenic acid inhibits tumorigenesis and enhances chemotherapeutic sensitivity of breast cancer cells through mitochondrial dysfunction. **W.-T. Liao**, C.-J. Li (Changhua; Taichung, Taiwan, R.O.C.)
292. The effect of cyclophilin A on cell invasion of colorectal cancer cells. **T. Yamamoto**, K. Mitamura, A. Taga (Osaka, Japan)
296. Effect of combined DNA methyltransferase and histone deacetylase inhibitors on hepatocellular carcinoma HepG2 cell line. M. Sanaei, **F. Kavooosi** (Jahrom, Iran)
298. Investigation of JCV in thyroid gland specimens. D. Stamatiou, **S.P. Derdas**, E. Symvoulakis, G. Sakorafas, O. Zoras, G. Sourvinos (Heraklion; Athens, Greece)
300. SARDH/PIPOX converts exogenously added sarcosine while providing methyl groups to methyl donor S-adenosyl methionine. **P. Michalek**, V. Strmiska, Z. Lackova, S. Krizkova, H. Buchtelova, R. Guran, L. Vanickova, S. Dostalova, O. Zitka, V. Adam, Z. Heger (Brno, Czech Republic)
301. Design and testing of lanthanide-based quantum dots for live cell and *in vivo* imaging. **H. Buchtelova**, V. Strmiska, S. Dostalova, P. Michalek, S. Krizkova, A. Moulick, D. Hynek, L. Richtera, V. Adam, Z. Heger (Brno, Czech Republic)
302. The effect of maple syrup extract on cell proliferation of malignant melanoma cells. **C. Kubota**, T. Yamamoto, A. Taga (Osaka, Japan)
305. Selective targeting of estrogen receptors- α and - β differently modulates differentiation and proliferation of cells involved in skin wound healing. **V. Gálová**, L. Varinská, P. Szabo, B. Dvořánková, H.-J. Gabius, K. Smetana Jr., P. Gál (Košice, Slovakia; Prague, Czech Republic; Munich, Germany)
307. Evaluation of the gallic acid effect on proteomic profile expression of Huh7 hepatocarcinoma cells infected with hepatitis C virus. **M. Govea Salas**, A.M. Rivas Estilla, S.A. Lozano Sepúlveda, T.B. Salas Villalobos, C.N. Aguilar González, R. Rodríguez Herrera, R.E. Belmares Cerda, A. Ilyina, J.A. Morlett Chávez (Saltillo; Monterrey, México)
308. MUC4 expression predicts radiotherapy response in breast cancer. **M. Zhang**, H. Sun, D. Chen, X. Yang, J. Du, M. Li, H. Duan, S. Zhou, Q. Tang (Kunming; Lincang, P.R. China)
310. Leptin receptor down-regulation during the progression of colorectal cancer. **M. Koda**, K. Jarzabek, A. Fudala, L. Kanczuga-Koda, K. Jakubowska, P. Samocik, A. Wincewicz, S. Sulkowski, W. Famulski, M. Baltaziak (Białystok; Kielce, Poland)
311. Novel AR genetic variant leading to complete androgen insensitivity syndrome and bilateral Sertoli cell tumor. K. Jarzabek, **M. Koda**, L. Kanczuga-Koda, A. Sobczynska-Tomaszewska, S. Wolczynski (Białystok; Warsaw, Poland)
313. ZEB1 as a key promoter of tumoral progress in advanced stages of prostate cancer. O. Orellana-Serradell, D. Herrera, E.A. Castellón, **H.R. Contreras** (Santiago, Chile)
317. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer. **W.-Y. Zhu**, Z.-D. Chai, L.-L. Tan, Z.-Y. Wang, Z.-J. Chen, H.-B. Le, Y.-K. Zhang (Zhoushan, P.R. China)
318. The hypoxia activated pro-drug evofosfamide exhibits tumour suppressive activity and cooperates with chemotherapy against primary and metastatic breast cancer. **V. Liapis**, I. Zinonos, A. Labrinidis, S. Hay, V. Ponomarev, V. Panagopoulos, A. Zysk, M. DeNichilo, W. Ingman, G.J. Atkins, D.M. Findlay, A.C.W. Zannettino, A. Evdokiou (Adelaide, South Australia; New York, NY, USA)
322. Beta-defensin-2, obesity and caries in children of 6 to 12 years. C. Arellanes, M. Toledo, V. Jiménez, B. Ávila, A. Flores, A. Torres, **C. Solórzano** (Oaxaca, Mexico)

323. MicroRNA-449a enhances radiosensitivity in prostate cancer cells. A. Mao, **R. Zhou**, H. Zhang (Lanzhou, P.R. China)
324. Disturbance of redox status enhances radiosensitivity of hepatocellular carcinoma. C. Sun, **L. Gan**, H. Zhang (Lanzhou, P.R. China)
325. Oxidative stress-inducing effects of L-amino acid oxidase on prostate cancer cells *in vitro*. **K.K. Tan**, J. Gunaratne, B.H. Bay, P. Gopalakrishnakone (Singapore, Republic of Singapore)
327. LncRNA H19/miR-675-5p regulate proliferation and apoptosis of vascular smooth muscle cell by targeting mitofusin-2. X. Xu, S. Cao, R. Song, W. Chen, Q. Guo, **S. Sun** (Shijiazhuang, P.R. China)
328. Upregulation of miR-195 accelerates oxidative stress-induced retinal endothelial cell injury by targeting mitofusin-2 in diabetic rats. R. Zhang, Q. Garrett, **S. Xu** (Shijiazhuang, P.R. China; Sydney, Australia)
329. The effect and mechanism of autophagy on vascular smooth muscle cell osteogenesis. **L.-H. Dong**, X.-H. Zhang, Q.-Q. Pei, M. Han (Shijiazhuang, P.R. China)
330. Cell motility is specifically inhibited by inhibitors of Piezo1. P. Gottlieb, **F. Sachs** (Buffalo, NY, USA)